Adjuvant-like effect of vaccinia virus 14K protein: A case study with malaria vaccine based on the circumsporozoite protein

Journal of Immunology

Volumn 188, Issue 12, 2012, Pages 6407-6417

  Vijayan, Aneesh ^a   Gómez, Carmen E ^a   Espinosa, Diego A ^b   Goodman, Alan G ^a   Sanchez Sampedro, Lucas ^a   Sorzano, Carlos Oscar S ^a   Zavala, Fidel ^b   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 12; INTERLEUKIN 6; MALARIA VACCINE; OLIGOMER; STAT1 PROTEIN; VACCINIA VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL STRAIN; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNOGENICITY; LONG TERM MEMORY; MACROPHAGE; MALARIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM YOELII; PRIORITY JOURNAL; SPOROZOITE; VACCINIA VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MICROSCOPY, CONFOCAL; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VACCINIA VIRUS; VIRAL PROTEINS;

EID: 84862611764     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1102492     Document Type: Article

References (65)

1. World Health Organization. World Malaria Report 2010. 2010. WHO Press, Geneva, Switzerland.
2. Good, M. F., and D. L. Doolan. 2010. Malaria vaccine design: immunological considerations. Immunity 33: 555-566.
3. Bejon, P., J. Lusingu, A. Olotu, A. Leach, M. Lievens, J. Vekemans, S. Mshamu, T. Lang, J. Gould, M. C. Dubois, et al. 2008. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age.N. Engl. J. Med. 359: 2521-2532.
4. Rosenberg, A. S. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J. 8: E501-E507. (Pubitemid 44294011)
5. Kastenmüller, K., U. Wille-Reece, R. W. Lindsay, L. R. Trager, P. A. Darrah, B. J. Flynn, M. R. Becker, M. C. Udey, B. E. Clausen, B. Z. Igyarto, et al. 2011. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 121: 1782-1796.
6. Ilyinskii, P. O., G. Thoidis, M. Y. Sherman, and A. Shneider. 2008. Adjuvant potential of aggregate-forming polyglutamine domains. Vaccine 26: 3223-3226.
7. Nussenzweig, V., and R. S. Nussenzweig. 1985. Circumsporozoite proteins of malaria parasites. Cell 42: 401-403.
8. Sinnis, P., P. Clavijo, D. Fenyö, B. T. Chait, C. Cerami, and V. Nussenzweig. 1994. Structural and functional properties of region II-plus of the malaria circumsporozoite protein. J. Exp. Med. 180: 297-306. (Pubitemid 24181078)
9. Lal, A. A., V. F. de la Cruz, J. A. Welsh, Y. Charoenvit, W. L. Maloy, and T. F. McCutchan. 1987. Structure of the gene encoding the circumsporozoite protein of Plasmodium yoelii: a rodent model for examining antimalarial sporozoite vaccines. J. Biol. Chem. 262: 2937-2940. (Pubitemid 17127536)
10. Kumar, K. A., P. Baxter, A. S. Tarun, S. H. Kappe, and V. Nussenzweig. 2009. Conserved protective mechanisms in radiation and genetically attenuated uis3(2) and uis4(2) Plasmodium sporozoites. PLoS ONE 4: e4480.
11. Singh, A. P., C. A. Buscaglia, Q. Wang, A. Levay, D. R. Nussenzweig, J. R. Walker, E. A. Winzeler, H. Fujii, B. M. Fontoura, and V. Nussenzweig. 2007. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131: 492-504. (Pubitemid 350007696)
12. Dunachie, S. J., M. Walther, J. M. Vuola, D. P. Webster, S. M. Keating, T. Berthoud, L. Andrews, P. Bejon, I. Poulton, G. Butcher, et al. 2006. A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/ AS02A and MVA-CS. Vaccine 24: 2850-2859.
13. +-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. J. Virol. 77: 11859-11866.
14. Sedegah, M., G. T. Brice, W. O. Rogers, D. L. Doolan, Y. Charoenvit, T. R. Jones, V. F. Majam, A. Belmonte, M. Lu, M. Belmonte, et al. 2002. Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8+-T-cell populations. Infect. Immun. 70: 3493-3499. (Pubitemid 34665985)
15. Sedegah, M., T. R. Jones, M. Kaur, R. Hedstrom, P. Hobart, J. A. Tine, and S. L. Hoffman. 1998. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 95: 7648-7653. (Pubitemid 28293307)
16. Wang, Z., P. J. Troilo, X. Wang, T. G. Griffiths, S. J. Pacchione, A. B. Barnum, L. B. Harper, C. J. Pauley, Z. Niu, L. Denisova, et al. 2004. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther. 11: 711-721. (Pubitemid 38519279)
17. Mor, G., G. Yamshchikov, M. Sedegah, M. Takeno, R. Wang, R. A. Houghten, S. Hoffman, and D. M. Klinman. 1996. Induction of neonatal tolerance by plasmid DNA vaccination of mice. J. Clin. Invest. 98: 2700-2705. (Pubitemid 26427395)
18. Kang, Y., P. A. Calvo, T. M. Daly, and C. A. Long. 1998. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite. J. Immunol. 161: 4211-4219. (Pubitemid 28469003)
19. Vázquez, M. I., and M. Esteban. 1999. Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus. J. Virol. 73: 9098-9109. (Pubitemid 29487063)
20. Bachmann, M. F., and R. M. Zinkernagel. 1997. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15: 235-270. (Pubitemid 27169281)
21. + T effector memory cells protect against liver-stage malaria. J. Immunol. 187: 1347-1357.
22. Gómez, C. E., J. L. Nájera, E. P. Jiménez, V. Jiménez, R. Wagner, M. Graf, M. J. Frachette, P. Liljeström, G. Pantaleo, and M. Esteban. 2007. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B. Vaccine 25: 2863-2885. (Pubitemid 46412565)
23. Maffei, C. M., L. F. Mirels, R. A. Sobel, K. V. Clemons, and D. A. Stevens. 2004. Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect. Immun. 72: 2338-2349. (Pubitemid 38419950)
24. Guerra, S., L. A. López-Fernández, A. Pascual-Montano, M. Muñoz, K. Harshman, and M. Esteban. 2003. Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J. Virol. 77: 6493-6506. (Pubitemid 36588419)
25. García-Arriaza, J., J. L. Nájera, C. E. Gómez, C. O. Sorzano, and M. Esteban. 2010. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVAB) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS ONE 5: e12395.
26. Bruña-Romero, O., J. C. Hafalla, G. González-Aseguinolaza, G. Sano, M. Tsuji, and F. Zavala. 2001. Detection of malaria liver-stages in mice infected through the bite of a single Anopheles mosquito using a highly sensitive real-time PCR. Int. J. Parasitol. 31: 1499-1502. (Pubitemid 32947005)
27. Gómez, C. E., J. L. Nájera, R. Sánchez, V. Jiménez, and M. Esteban. 2009. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 27: 3165-3174.
28. Ophorst, O. J., K. Radosević, K. Ouwehand, W. van Beem, R. Mintardjo, J. Sijtsma, J. Kaspers, A. Companjen, L. Holterman, J. Goudsmit, and M. J. Havenga. 2007. Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence. Vaccine 25: 1426-1436. (Pubitemid 46074299)
29. Bergmann-Leitner, E. S., E. H. Duncan, W. W. Leitner, A. Neutzner, T. Savranskaya, E. Angov, and G. C. Tsokos. 2007. C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine 25: 7732-7736. (Pubitemid 47595371)
30. Sharma, A., A. Eapen, and S. K. Subbarao. 2004. Parasite killing in Plasmodium vivax malaria by nitric oxide: implication of aspartic protease inhibition. J. Biochem. 136: 329-334. (Pubitemid 39545792)
31. Stoute, J. A., M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garçon, U. Krzych, and M. Marchand. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria: RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336: 86-91. (Pubitemid 27020884)
32. Langhorne, J., F. M. Ndungu, A. M. Sponaas, and K. Marsh. 2008. Immunity to malaria: more questions than answers. Nat. Immunol. 9: 725-732. (Pubitemid 351859155)
33. Charoenvit, Y., S. Mellouk, C. Cole, R. Bechara, M. F. Leef, M. Sedegah, L. F. Yuan, F. A. Robey, R. L. Beaudoin, and S. L. Hoffman. 1991. Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J. Immunol. 146: 1020-1025.
34. Kester, K. E., D. A. McKinney, N. Tornieporth, C. F. Ockenhouse, D. G. Heppner, T. Hall, U. Krzych, M. Delchambre, G. Voss, M. G. Dowler, et al; RTS,S Malaria Vaccine Evaluation Group. 2001. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 183: 640-647. (Pubitemid 32147521)
35. Gerberick, G. F., L. W. Cruse, C. M. Miller, E. E. Sikorski, and G. M. Ridder. 1997. Selective modulation of T cell memory markers CD62L and CD44 on murine draining lymph node cells following allergen and irritant treatment. Toxicol. Appl. Pharmacol. 146: 1-10. (Pubitemid 27406391)
36. Waters, W. R., T. E. Rahner, M. V. Palmer, D. Cheng, B. J. Nonnecke, and D. L. Whipple. 2003. Expression of L-Selectin (CD62L), CD44, and CD25 on activated bovine T cells. Infect. Immun. 71: 317-326. (Pubitemid 36026035)
37. Krzych, U., T. Jareed, H. T. Link, L. D. Loomis, andW. R. Ballou. 1992. Distinct T cell specificities are induced with the authentic versus recombinant Plasmodium berghei circumsporozoite protein. J. Immunol. 148: 2530-2538.
38. Shio, M. T., F. A. Kassa, M. J. Bellemare, and M. Olivier. 2010. Innate inflammatory response to the malarial pigment hemozoin. Microbes Infect. 12: 889-899.
39. Arnold, L., R. K. Tyagi, P. Mejia, N. Van Rooijen, J. L. Pérignon, and P. Druilhe. 2010. Analysis of innate defences against Plasmodium falciparum in immuno-deficient mice. Malar. J. 9: 197.
40. Nussler, A., S. Pied, J. Goma, L. Rénia, F. Miltgen, G. E. Grau, and D. Mazier. 1991. TNF inhibits malaria hepatic stages in vitro via synthesis of IL-6. Int. Immunol. 3: 317-321.
41. Mettens, P., P. M. Dubois, M. A. Demoitié, B. Bayat, M. N. Donner, P. Bourguignon, V. A. Stewart, D. G. Heppner, Jr., N. Garçon, and J. Cohen. 2008. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 26: 1072-1082.
42. Wiley, S. R., V. S. Raman, A. Desbien, H. R. Bailor, R. Bhardwaj, A. R. Shakri, S. G. Reed, C. E. Chitnis, and D. Carter. 2011. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3: 93ra69.
43. Imada, K., and W. J. Leonard. 2000. The Jak-STAT pathway. Mol. Immunol. 37: 1-11. (Pubitemid 30316189)
44. Späth, G. F., P. Schlesinger, R. Schreiber, and S. M. Beverley. 2009. A novel role for Stat1 in phagosome acidification and natural host resistance to intracellular infection by Leishmania major. PLoS Pathog. 5: e1000381.
45. Liew, F. Y. 1994. Regulation of nitric oxide synthesis in infectious and autoimmune diseases. Immunol. Lett. 43: 95-98.
46. + T cells surrounding Plasmodium berghei-infected hepatocytes. Infect. Immun. 65: 3882-3888.
47. White, M. T., J. T. Griffin, E. M. Riley, C. J. Drakeley, A. M. Moorman, P. O. Sumba, J. W. Kazura, A. C. Ghani, and C. C. John. 2011. Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. Proc. Biol. Sci. 278: 1298-1305
48. Oliveira, G. A., K. Wetzel, J. M. Calvo-Calle, R. Nussenzweig, A. Schmidt, A. Birkett, F. Dubovsky, E. Tierney, C. H. Gleiter, G. Boehmer, et al. 2005. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect. Immun. 73: 3587-3597. (Pubitemid 40745903)
49. Scheiblhofer, S., D. Chen, R. Weiss, F. Khan, S. Mostböck, K. Fegeding, W. W. Leitner, J. Thalhamer, and J. A. Lyon. 2001. Removal of the circumsporozoite protein (CSP) glycosylphosphatidylinositol signal sequence from a CSP DNAvaccine enhances induction of CSP-specific Th2 type immune responses and improvesprotection against malaria infection. Eur. J. Immunol. 31: 692-698. (Pubitemid 32237104)
50. Wang, R., Y. Charoenvit, G. Corradin, R. Porrozzi, R. L. Hunter, G. Glenn, C. R. Alving, P. Church, and S. L. Hoffman. 1995. Induction of protective polyclonal antibodies by immunization with Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immunol. 155: 1637.
51. Kaba, S. A., C. Brando, Q. Guo, C. Mittelholzer, S. Raman, D. Tropel, U. Aebi, P. Burkhard, and D. E. Lanar. 2009. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol. 183: 7268-7277.
52. Overstreet, M. G., I. A. Cockburn, Y. C. Chen, and F. Zavala. 2008. Protective CD8 T cells against Plasmodium liver stages: immunobiology of an "unnatural"immune response. Immunol. Rev. 225: 272-283.
53. + T-cell- mediated protective immunity against malaria. Proc. Natl. Acad. Sci. USA 90: 5214-5218.
54. Stewart, V. A., S. M. McGrath, P. M. Dubois, M. G. Pau, P. Mettens, J. Shott, M. Cobb, J. R. Burge, D. Larson, L. A. Ware, et al. 2007. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/ AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75: 2283-2290. (Pubitemid 46744316)
55. Butler, N. S., N. W. Schmidt, and J. T. Harty. 2010. Differential effector pathways regulate memory CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites. J. Immunol. 184: 2528-2538.
56. Li, C., and J. Langhorne. 2000. Tumor necrosis factor α p55 receptor is important for development of memory responses to blood-stage malaria infection. Infect. Immun. 68: 5724-5730.
57. Pombo, D. J., G. Lawrence, C. Hirunpetcharat, C. Rzepczyk, M. Bryden, N. Cloonan, K. Anderson, Y. Mahakunkijcharoen, L. B. Martin, D. Wilson, et al. 2002. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360: 610-617. (Pubitemid 35232195)
58. Hoffman, S. L., J. M. Crutcher, S. K. Puri, A. A. Ansari, F. Villinger, E. D. Franke, P. P. Singh, F. Finkelman, M. K. Gately, G. P. Dutta, and M. Sedegah. 1997. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat. Med. 3: 80-83. (Pubitemid 27019146)
59. Delaloye, J., T. Roger, Q. G. Steiner-Tardivel, D. Le Roy, M. Knaup Reymond, S. Akira, V. Petrilli, C. E. Gomez, B. Perdiguero, J. Tschopp, et al. 2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2- TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5: e1000480.
60. Olotu, A., J. Lusingu, A. Leach, M. Lievens, J. Vekemans, S. Msham, T. Lang, J. Gould, M. C. Dubois, E. Jongert, et al. 2011. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect. Dis. 11: 102-109.
61. E and protection against P falciparum clinical malaria. PLoS ONE 6: e25786.
62. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4: 397-402.
63. Yoshida, S., D. Kondoh, E. Arai, H. Matsuoka, C. Seki, T. Tanaka, M. Okada, and A. Ishii. 2003. Baculovirus virions displaying Plasmodium berghei circumsporozoite protein protect mice against malaria sporozoite infection. Virology 316: 161-170. (Pubitemid 37346317)
64. Tartz, S., H. Rüssmann, J. Kamanova, P. Sebo, A. Sturm, V. Heussler, B. Fleischer, and T. Jacobs. 2008. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. Vaccine 26: 5935-5943.
65. Gonzalez-Aseguinolaza, G., L. Van Kaer, C. C. Bergmann, J. M. Wilson, J. Schmieg, M. Kronenberg, T. Nakayama, M. Taniguchi, Y. Koezuka, and M. Tsuji. 2002. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195: 617-624. (Pubitemid 34461506)